Document is current
Any future updates will be listed below
-
Authors
Tillmann, Bourke W. https://orcid.org/0000-0002-7815-5972
Hallet, Julie https://orcid.org/0000-0001-5108-1072
Sutradhar, Rinku
Guttman, Matthew P.
Coburn, Natalie
Chesney, Tyler R. https://orcid.org/0000-0002-2295-6869
Zuckerman, Jesse https://orcid.org/0000-0001-5190-0816
Mahar, Alyson https://orcid.org/0000-0002-6862-3760
Chan, Wing C.
Haas, Barbara
,
Hsu, Amy
Manuel, Douglas
Wright, Frances
Gandell, Dov
Menjak, Ines
Gotlib-Conn, Lesley
Paladino, Grace
Galuzzo, Pietro
-
Funding
Funding for this research was provided by:
Ontario Institute for Cancer Research (P.HSR.156)
Sunnybrook AFP Innovation Fund
- License Information
-
More Information
Article History
Received: 29 November 2022
Accepted: 27 March 2023
First Online: 25 April 2023
Declarations
:
: This study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board.
: N/A, no individual person’s data.
: JH has received speaking honoraria from Ipsen Biopharmaceuticals Canada, Novartis Oncology, and Advanced Accelerator Applications. NC receives salary support from Cancer Care Ontario as Lead for Patient-Reported Outcomes, and an honorarium from Astra-Zeneca.
